COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

Few know this better than Evgeny Oystacher, a veteran entrepreneur with over 25 years of experience in global markets and ...

Many venture industry observers have wondered whether Andreessen Horowitz, a firm that manages $45 billion, has its sights on ...

As well as chalking up quite a resume and reducing admirers to tears playing Dexter Mayhew in Netflix's One Day, Leo Woodall ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.

We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to ...

With another JP Morgan in the rearview mirror ... Andrew Obershain, CEO of bluebird bio, said as much on stage. A year before the FDA approved his company’s gene therapy for sickle cell ...

Biotech firms explore US-based production to sidestep potential tariffs, but time-consuming, costly process lies ahead US ...

Pioneering license agreement with BrainTransporter signed with BMS worth up to USD 1.35 billion plus royalties Events during the fourth quarter 2024 The Australian Medicines Agency (TGA) decided not ...